Today, Evotec SE – a Frankfurt Stock Exchange-listed MDAX/TecDAX and NASDAQ-traded company – and the European Investment Bank (EIB) are pleased to announce a € 150 million loan facility granted to Evotec. This generous support will be used to fund the company’s research and development initiatives, make equity investments, and construct the brand-new J.POD ® biologics manufacturing facility located on the Evotec Campus Curie in Toulouse, France.
The European Investment Bank (EIB) is once again expressing its support for Evotec, announcing a new €150 million financing. This is the second investment from the EIB, after a €75 million agreement in 2017. To mark the occasion, the signing of the agreement will take place in Toulouse, during a visit to the new biologics manufacturing facility the company is building.
Evotec is committed to providing global access to first- and best-in-class precision medicines. We are proud to collaborate with the world’s Top 20 Pharma companies, as well as more than 800 biotechnology companies, academic institutions, and other health care stakeholders. Our goal is to advance our understanding of disease and develop novel and more targeted therapeutic approaches. With these partnerships, we are striving to make a positive impact on patients’ health and well-being.
The European Investment Bank has provided a unique, innovative and flexible loan of up to € 150 million to Evotec, a biopharmaceutical company, to support its business strategy and fund internal R&D activities, equity investments, and the new biologics manufacturing facility, J.POD® Toulouse, France (EU). This loan, with a low fixed interest rate plus a reward-sharing component for the EIB, will be invested over a period of three years, with each tranche maturing seven years after draw down. This financing is a significant step towards Evotec’s goal of becoming a leader in the biopharmaceutical industry.
The European Investment Bank (EIB) is providing funds to Evotec, a global leader in precision medicine, to help expand its innovative research and development (R&D) activities and create new partnering opportunities. Since 2016, Evotec has been an operational investor in over 30 early-stage biotechnology companies, with over 90 active projects worldwide. This financing from the EIB will help Evotec to further this progress and create an even more diverse portfolio of projects.
The European Investment Bank is investing in a highly innovative biologics manufacturing facility in Evotec’s Campus Curie, J.POD® Toulouse, France (EU). This is the first of its kind in the EU, and will bring advanced biomanufacturing to the region, providing much needed clinical and commercial production capacity. The construction of J.POD® Toulouse, France (EU) is also supported by the French government, the Occitanie Region, Bpifrance, the Haute-Garonne prefecture and Toulouse Métropole, with up to €50m in funding. This cutting-edge facility is set to revolutionize the biologics industry in Europe, and will revolutionize the way biologics are produced.
We are thrilled to have entered into a second financing agreement with the European Investment Bank. This innovative financing model, with its highly attractive terms, will enable us to create new R&D partnering opportunities and establish Europe’s first J.POD® biologics manufacturing plant. This second agreement strengthens our already excellent relationship with the EIB, which we first entered into in 2017. Through their support, the EIB is helping us to fulfil our mission of ‘Together for Medicines that Matter’. We are honoured to be able to work with them to drive innovation in the EU.
The European Investment Bank is proud to be supporting Evotec’s investments in research, development and innovation with a second financing agreement. This is a clear indication of our commitment to supporting European biotech firms as they compete on a global stage. The investment will have a meaningful impact on the Toulouse region, as it will finance a 12,000 square metre plant that is set to create over 200 jobs. Vice President Ambroise Fayolle expressed his delight at the agreement, noting its significance for the region.
Today, at Evotec’s Campus Curie in Toulouse, a momentous ceremony will be taking place. This is where Members of Evotec’s Management Board and the European Investment Bank’s Vice President Ambroise Fayolle will be signing a financing agreement. This is the culmination of a close partnership between Evotec and the kENUP Foundation – an NGO dedicated to promoting innovation in Europe – and builds on the success of a previous loan of € 75 m from the EIB in 2017.
The European Investment Bank (EIB) is leading the way in driving the next wave of innovation, particularly in the health sector. In response to the COVID-19 pandemic, the EIB allocated a staggering EUR 6 billion to health sector investments, with the aim of supporting medical infrastructure, additional research activities, and other vaccine and treatment financing. In 2022, the EIB devoted a significant 31% of its 8.4 billion euro financing in France to innovation, equating to 2.7 billion euros. Furthermore, the EIB is a major contributor to the green transition, supporting the European Union’s efforts to achieve a low-carbon, sustainable growth model.